Android app on Google Play

Jefferies Lowers Numbers on Impax Laboratories (IPXL)

June 25, 2012 8:08 AM EDT Send to a Friend
Get Alerts IPXL Hot Sheet
Price: $26.34 +1.11%

Rating Summary:
    5 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 23 | Down: 10 | New: 20
Trade IPXL Now!
Join SI Premium – FREE
Jefferies lowered estimates and its price target on Impax Laboratories (NASDAQ: IPXL) from $21.00 to $20.00 citing AXR competition.

The firm comments, "We've been uneasy with IPXL geared to Gx AXR revenues at risk of competition and ending completely in ’14. News of Actavis/WPI’s AXR approval means an immediate hit to ’12-’14 REV, partially offset by lower royalty payout. This might pave the way for IPXL’s own AXR approval but we doubt it – some speculate Concerta as well – but certain losses trump uncertain gains."

FY12 EPS goes from $1.92 to $1.88 and FY13 goes from $1.42 to $1.29.

For an analyst ratings summary and ratings history on Impax Laboratories click here. For more ratings news on Impax Laboratories click here.

Shares of Impax Laboratories closed at $22.85 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment